Skip to main content

Table 2 Clinical characteristics of 7 patients with diffuse large B cell lymphoma

From: Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma

Characteristic

n (%)

Middle Age (range)

34 years old (18-50)

Gender

 

 Male

1 (14.3)

 Female

6 (85.7)

Clinical staging

 

 II

2 (28.6)

 IV

5 (71.4)

Performance status score (Eastern Cooperative Oncology Group)

 

 0

5 (71.4)

 1

1 (14.3)

 2

1 (14.3)

International prognostic index

 

 0-1

1 (14.3)

 2

4 (57.1)

 3

2 (28.6)

Bulky disease (longest diameter ≥ 7.5 cm by CT scan)

 

 Mediastinum

5 (71.4)

 Abdominal cavity

2 (28.6)

B symptoms

 

Weight lose

2 (28.6)

Fever

1 (14.3)

Laboratory abnormalities

 

 LDH (>240 IU/L)

6 (85.7)

 C-reactive protein increased

6 (85.7)